X‑Chem Acquires ComInnex
X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
UPPTHERA and ComInnex sign research collaboration for the development of novel Proteolysis-Targeting Chimera candidates
UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and ComInnex, a specialist chemistry group with expertise in the design and synthesis of small molecules for drug discovering will accelerate the development of new proteolysis targeting chimeras (commonly known as PROTAC) or Molecular Glues. Within the framework of the collaboration, UPPTHERA and ComInnex will co-verify a number of potential novel E3 ligase ligands which have been designed by ComInnex and co-develop TPD chimera molecules to which the novel E3 ligase ligands will be applied.
Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands
We are very proud to be collaborating with Merck Millipore to develop degrader building blocks, in this case for IAP and containing three novel, in silico-derived lead compounds. Together, these reagents accelerate synthesis of IAP-mediated degraders at early stages of TPD research and assessment.
Click below to explore the Advantages of IAP In Silico-Derived Ligands!
Novel approach for insect control: E3 ligase ligand library for potential degradation of vital insect proteins
Come and see how we are applying protein degradation techniques to crop protection at our poster at the ACS Fall meeting.
InnoStudio Launches a Consortium for Developing Coronavirus Drugs Based on Simultaneous Research in Space and Earth Environments
We are happy to announce to be involved in drug research project – advancing our knowledge of synthesis into space … the final frontier! Curious where it will lead us and hope others will join this intitiative too!
ComInnex Inc. is open for business as usual, accepting chemistry projects (large or small). To keep things moving we offer rapid onboarding (fast contract turnaround) and favourable rates.
If chemistry is currently a bottleneck come and talk to us!
ComInnex takes seriously the threat to its staff and customers of the corona virus. We comply with all local regulations and are committed to global efforts to “flatten the curve”. To this extent we have implemented a range of measures to keep our facilities operating as well as possible under current circumstances.
Photocatalytic reactions in flow
We are proud to share with you that our Associate Principal Scientist, Gellert Sipos held two presentations at the ACS fall meeting. He talked about photocatalytic reactions in flow and on the application of a novel mutliwavelength photoreactor for batch and flow chemistry developed by ComInnex Inc. and ThalesNano Inc.
InnoStudio, ComInnex and ThalesNano enter into photochemistry collaboration with Technical University Eindhoven
Proud to share with you that ComInnex Inc. has entered a photochemistry collaboration with Eindhoven University of Technology.
Global chemistry service and research organization reinforces its commitment to deliver the highest quality services to the life science industry
ComInnex Inc. announces ISO 9001:2015 certification – Global chemistry service and research organization reinforces its commitment to deliver the highest quality services to the life science industry.
Open collaboration project
ComInnex, Inc. has started an open collaboration type of project to support its activities on designing and synthesizing a large number of novel chemical building blocks to be used subsequently by companies in creating and / or enriching their DNA-encoded libraries. The project currently involves large pharmaceutical companies as well as a biotech service provider from all around the globe, and it is still open to join.
Please contact firstname.lastname@example.org for further information
Affinity-Based Lead Discovery Using DNA Encoded Chemistry
ComInnex, Inc. has attended the Chemical Biology session “Affinity-Based Lead Discovery Using DNA Encoded Chemistry” at SLAS2018, where interesting developments from this very exciting area were discussed with key opinion leaders.
Please contact email@example.com for further information
Dr. Ferenc Darvas is awarded an ACS Fellowship
We are happy to announce that in recognition of his outstanding achievements towards the field of chemistry, Dr. Ferenc Darvas, the president of ThalesNano Inc., president of ComInnex Inc. and a number of other companies that he has founded in the field of chemistry research and innovation, has been honored and selected as a member of the 2016 class of Fellows of the American Chemical Society.
Design of Novel Peptide Drug Conjugate Warheads as Novel Potential Anticancer Agents
ComInnex Inc. has been awarded a grant (NVKP_16-1-2016-0036) by the Hungarian government for a consortium working on the development of bioconjugates and modules for the targeted treatment of high mortality tumor diseases. The project is for 3 years and was started in January 2017 with a close collaboration with Semmelweis University and Eotvos Lorand University. New anticancer drug candidates are targeted to be developed based on a close cooperation of the members. The essence of the research is around the development of new Peptide (Antibody) Drug Conjugates (ADCs).
Development of a flow chemistry and pyrolysis platform for pharmaceutical, cosmetics and agrochemical applications in combination with novel nanoformulation processes
ComInnex Inc. has been awarded a grant (KMR_12-1-2012-0218.) for the development of a flow chemistry and pyrolysis platform for pharmaceutical, cosmetics and agrochemical applications in combination with novel nanoformulation processes.
Developing a high-throughput innovative chemistry and informatics platform to support pharmaceutical drug discovery projects
ComInnex, Inc. has been awarded a grant (GINOP-2.1.1-15-2015-00069) for developing a high-throughput innovative chemistry and informatics platform to support pharmaceutical drug discovery projects.